Katja Rosenkranz

Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany.

Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany.

Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany.

Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.

Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.

Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany.

V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent.

Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.